{"entity":{"edinet_code":"E02632","sec_code":"7459","name_ja":"株式会社メディパルホールディングス","name_en":"MEDIPAL HOLDINGS CORPORATION","industry":"卸売業","industry_en":"Wholesale Trade"},"names_note":"English company names are as filed: each company's own annual report states its English name on the cover page. For a company that files no annual report, EDINET's filer registry is used instead. The as-filed Japanese name is always returned alongside.","filing":{"doc_id":"S100YI1C","filer_name":"株式会社メディパルホールディングス","filer_name_en":"MEDIPAL HOLDINGS CORPORATION","period_end":"2026-03-31","filed_date":"2026-06-23","sha256":"7d2742b0d4dca3ba9e0d26643a69eb4d09d86c63b57453e5814f957640f1485e","status":"clean"},"basis":{"measurement":"carrying_amount","entity_scope":"holdco_consolidated","share_scope":"both","trust_included":"unknown","as_of":"2026-03-31","period_type":"annual","labels":{"measurement":"Balance-sheet carrying amount. Under Japanese GAAP listed equities are carried at market with the valuation difference in other comprehensive income, so carrying amount and acquisition cost diverge enormously on positions bought decades ago.","entity_scope":"Every disclosing entity in the filing, summed — the reporting company plus each group holder it names.","share_scope":"Listed and unlisted shares together.","trust_included":"The filing does not state whether retirement-benefit-trust shares are included. Never guessed — shares contributed to such a trust leave the holder's balance sheet while the settlor normally keeps the right to instruct the vote.","period_type":"From an annual securities report (有価証券報告書). The policy shareholding table appears only in the annual report."},"not_comparable":"Figures are balance-sheet CARRYING AMOUNT at fiscal year end, from the annual securities report. They are NOT comparable with the acquisition-cost or book-value-reduction figures quoted in press coverage and IR presentations, and NOT comparable with interim (half-year) figures, which this product does not hold. Always state the basis with the number, and use check_claim before setting one of our figures against a published one."},"basis_note":"The basis every yen figure on this response is on. entity_scope is read from the filing's own disclosing entities, not assumed: scale_entities and flows each carry their own entity_scope and share_scope, and a figure quoted for one entity is not the group figure.","holdings":[{"holder_table":"reporting","held_name_raw":"大塚ホールディングス㈱","held_name_en":"Otsuka Holdings Co., Ltd.","held_sec_code":"4578","match_status":"matched","shares":5316000,"book_value_yen":58529000000,"prior_shares":5316000,"prior_book_value_yen":41214000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":1.006567651323799,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":7.35844525829175,"pct_of_holder_assets":3.0452101506658162,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"second_largest","held_name_raw":"㈱クリエイトＳＤホールディングス","held_name_en":"CREATE SD HOLDINGS CO.,LTD.","held_sec_code":"3148","match_status":"matched","shares":1731916,"book_value_yen":5723000000,"prior_shares":1730920,"prior_book_value_yen":5033000000,"purpose_ja":"同社とは当社グループ会社が取り扱う商品の販売取引があり、中長期視点で取引深耕・拡大を目的に株式を保有しております。また、同社とは相応の取引金額を有しております。定量的な保有効果については、（注）に記載しております。なお、株式数の増加については取引拡大に向け、同社の共栄会等に加入しており、同会における持株会での株式取得によるものであります。","reciprocal":"無","pct_outstanding":2.680887327583263,"pct_unavailable":null,"pct_basis_period_end":"2026-05-31","pct_share_classes":1,"pct_of_holder_equity":0.7195130997147343,"pct_of_holder_assets":0.29776243729194873,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"second_largest","held_name_raw":"㈱トライアルホールディングス","held_name_en":"TRIAL Holdings, Inc.","held_sec_code":"141A","match_status":"matched","shares":1200000,"book_value_yen":5040000000,"prior_shares":1200000,"prior_book_value_yen":2616000000,"purpose_ja":"同社とは当社グループ会社が取り扱う商品の販売取引があり、中長期視点で取引深耕・拡大を目的に株式を保有しております。また、同社とは相応の取引金額を有しております。定量的な保有効果については、（注）に記載しております。","reciprocal":"無","pct_outstanding":0.9774175812987436,"pct_unavailable":null,"pct_basis_period_end":"2026-06-30","pct_share_classes":1,"pct_of_holder_equity":0.6336442464725252,"pct_of_holder_assets":0.2622265741658958,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱ＥＭシステムズ","held_name_en":null,"held_sec_code":null,"match_status":"unmatched","shares":7063200,"book_value_yen":4626000000,"prior_shares":7063200,"prior_book_value_yen":5601000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":0.5815948976551392,"pct_of_holder_assets":0.24068653414512575,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"小野薬品工業㈱","held_name_en":"ONO　PHARMACEUTICAL　CO.,　LTD.","held_sec_code":"4528","match_status":"matched","shares":1677615,"book_value_yen":4211000000,"prior_shares":1677615,"prior_book_value_yen":2688000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.35074116825285584,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.5294198257729769,"pct_of_holder_assets":0.21909446504217997,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"second_largest","held_name_raw":"㈱マツキヨココカラ＆カンパニー","held_name_en":"MatsukiyoCocokara&Co.","held_sec_code":"3088","match_status":"matched","shares":1548122,"book_value_yen":3910000000,"prior_shares":1545109,"prior_book_value_yen":3616000000,"purpose_ja":"同社とは当社グループ会社が取り扱う商品の販売取引があり、中長期視点で取引深耕・拡大を目的に株式を保有しております。また、同社とは相応の取引金額を有しております。定量的な保有効果については、（注）に記載しております。なお、株式数の増加については取引拡大に向け、同社の共栄会等に加入しており、同会における持株会での株式取得によるものであります。","reciprocal":"無","pct_outstanding":0.38840133337605076,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.49157718327531214,"pct_of_holder_assets":0.2034337113072723,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"第一三共㈱","held_name_en":"DAIICHI SANKYO COMPANY, LIMITED","held_sec_code":"4568","match_status":"matched","shares":1285089,"book_value_yen":3554000000,"prior_shares":2570089,"prior_book_value_yen":9023000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.0700768850891569,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.4468197722149512,"pct_of_holder_assets":0.18491135805269712,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"塩野義製薬㈱","held_name_en":"Shionogi & Co., Ltd.","held_sec_code":"4507","match_status":"matched","shares":1014795,"book_value_yen":3520000000,"prior_shares":1014795,"prior_book_value_yen":2279000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.11800278099784692,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.4425451880125572,"pct_of_holder_assets":0.18314236925872085,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"エ－ザイ㈱","held_name_en":null,"held_sec_code":null,"match_status":"unmatched","shares":701975,"book_value_yen":3419000000,"prior_shares":701975,"prior_book_value_yen":2909000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":0.4298471584701515,"pct_of_holder_assets":0.17788743195896778,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"武田薬品工業㈱","held_name_en":"Takeda Pharmaceutical Company Limited","held_sec_code":"4502","match_status":"matched","shares":512263,"book_value_yen":2901000000,"prior_shares":512263,"prior_book_value_yen":2260000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"無","pct_outstanding":0.03232067791958031,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.3647226109160308,"pct_of_holder_assets":0.15093636739191738,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"second_largest","held_name_raw":"イオン㈱","held_name_en":"AEON CO.,LTD.","held_sec_code":"8267","match_status":"matched","shares":1382033,"book_value_yen":2604000000,"prior_shares":457157,"prior_book_value_yen":1714000000,"purpose_ja":"同社とは当社グループ会社が取り扱う商品の販売取引があり、中長期視点で取引深耕・拡大を目的に株式を保有しております。また、同社とは相応の取引金額を有しております。定量的な保有効果については、（注）に記載しております。なお、株式数の増加については株式分割、及び取引拡大に向け、同社の共栄会等に加入しており、同会における持株会での株式取得によるものであります。","reciprocal":"無","pct_outstanding":0.049969223363260026,"pct_unavailable":null,"pct_basis_period_end":"2026-02-28","pct_share_classes":1,"pct_of_holder_equity":0.3273828606774713,"pct_of_holder_assets":0.13548372998571281,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":["share split"],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"テルモ㈱","held_name_en":"TERUMO CORPORATION","held_sec_code":"4543","match_status":"matched","shares":1096468,"book_value_yen":2311000000,"prior_shares":2192968,"prior_book_value_yen":6133000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.07433262674262388,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.29054600269801695,"pct_of_holder_assets":0.12023920890821134,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"second_largest","held_name_raw":"ライオン㈱","held_name_en":"Lion Corporation","held_sec_code":"4912","match_status":"matched","shares":1359503,"book_value_yen":2262000000,"prior_shares":1359503,"prior_book_value_yen":2409000000,"purpose_ja":"同社とは当社グループ会社が取り扱う商品の仕入取引があり、中長期視点で取引深耕・拡大を目的に株式を保有しております。また、同社とは相応の取引金額を有しております。定量的な保有効果については、（注）に記載しております。","reciprocal":"無","pct_outstanding":0.4902349064181311,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":0.28438557252397856,"pct_of_holder_assets":0.11768978388159845,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"second_largest","held_name_raw":"㈱クスリのアオキホールディングス","held_name_en":"KUSURI NO AOKI HOLDINGS CO., LTD.","held_sec_code":"3549","match_status":"matched","shares":513200,"book_value_yen":1985000000,"prior_shares":513200,"prior_book_value_yen":1744000000,"purpose_ja":"同社とは当社グループ会社が取り扱う商品の販売取引があり、中長期視点で取引深耕・拡大を目的に株式を保有しております。また、同社とは相応の取引金額を有しております。定量的な保有効果については、（注）に記載しております。","reciprocal":"無","pct_outstanding":0.5404205508077455,"pct_unavailable":null,"pct_basis_period_end":"2026-05-20","pct_share_classes":1,"pct_of_holder_equity":0.2495602835809449,"pct_of_holder_assets":0.10327772811890934,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱エムティーアイ","held_name_en":"MTI Ltd.","held_sec_code":"9438","match_status":"matched","shares":3150000,"book_value_yen":1946000000,"prior_shares":3150000,"prior_book_value_yen":2668000000,"purpose_ja":"・当社グループ事業の円滑な取引関係維持と資本業務提携による関係強化のため、保有しております。なお、当社は、ヘルスケア・生活情報等のモバイルサービス事業を行う同社と、医療のＩＴ化に資するヘルスケアサービスの提供を目的として、資本業務提携に関する基本合意書を締結しております。  ・定量的な保有効果については、（注）１に記載しております。","reciprocal":"無","pct_outstanding":5.72570076215439,"pct_unavailable":null,"pct_basis_period_end":"2025-09-30","pct_share_classes":1,"pct_of_holder_equity":0.2446570840546694,"pct_of_holder_assets":0.1012485939140542,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"second_largest","held_name_raw":"ロート製薬㈱","held_name_en":"ROHTO PHARMACEUTICAL CO.,LTD.","held_sec_code":"4527","match_status":"matched","shares":663040,"book_value_yen":1596000000,"prior_shares":663040,"prior_book_value_yen":1482000000,"purpose_ja":"同社とは当社グループ会社が取り扱う商品の仕入取引があり、中長期視点で取引深耕・拡大を目的に株式を保有しております。また、同社とは相応の取引金額を有しております。定量的な保有効果については、（注）に記載しております。","reciprocal":"有","pct_outstanding":0.29342686904847937,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.2006540113829663,"pct_of_holder_assets":0.08303841515253366,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"日本新薬㈱","held_name_en":"Nippon Shinyaku Co., Ltd.","held_sec_code":"4516","match_status":"matched","shares":269372,"book_value_yen":1377000000,"prior_shares":269372,"prior_book_value_yen":1024000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.39965588632949334,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.17312066019695777,"pct_of_holder_assets":0.07164404615603938,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱ツムラ","held_name_en":"TSUMURA & CO.","held_sec_code":"4540","match_status":"matched","shares":255600,"book_value_yen":957000000,"prior_shares":848159,"prior_book_value_yen":3659000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。・事業関係のより一層の強化のため、取引先持株会による取得により、保有株式数が1,185株増加しております。","reciprocal":"有","pct_outstanding":0.33949695636196975,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.120316972990914,"pct_of_holder_assets":0.049791831642214734,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"明治ホールディングス㈱","held_name_en":"Meiji Holdings Co.,Ltd.","held_sec_code":"2269","match_status":"matched","shares":237308,"book_value_yen":915000000,"prior_shares":237308,"prior_book_value_yen":771000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.08753458108018385,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.11503660427030962,"pct_of_holder_assets":0.04760661019083227,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"second_largest","held_name_raw":"㈱平和堂","held_name_en":"HEIWADO CO.,LTD.","held_sec_code":"8276","match_status":"matched","shares":284591,"book_value_yen":844000000,"prior_shares":277180,"prior_book_value_yen":704000000,"purpose_ja":"同社とは当社グループ会社が取り扱う商品の販売取引があり、中長期視点で取引深耕・拡大を目的に株式を保有しております。また、同社とは相応の取引金額を有しております。定量的な保有効果については、（注）に記載しております。なお、株式数の増加については取引拡大に向け、同社の共栄会等に加入しており、同会における持株会での株式取得によるものであります。","reciprocal":"無","pct_outstanding":0.5754548026214554,"pct_unavailable":null,"pct_basis_period_end":"2026-02-20","pct_share_classes":1,"pct_of_holder_equity":0.1061102666711927,"pct_of_holder_assets":0.04391254535635239,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"参天製薬㈱","held_name_en":"SANTEN PHARMACEUTICAL CO., LTD.","held_sec_code":"4536","match_status":"matched","shares":466545,"book_value_yen":833000000,"prior_shares":466545,"prior_book_value_yen":661000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.14502159780332463,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.10472731295865345,"pct_of_holder_assets":0.04334022545241888,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"second_largest","held_name_raw":"㈱イズミ","held_name_en":"IZUMI CO., LTD.","held_sec_code":"8273","match_status":"matched","shares":697735,"book_value_yen":723000000,"prior_shares":230538,"prior_book_value_yen":729000000,"purpose_ja":"同社とは当社グループ会社が取り扱う商品の販売取引があり、中長期視点で取引深耕・拡大を目的に株式を保有しております。また、同社とは相応の取引金額を有しております。定量的な保有効果については、（注）に記載しております。なお、株式数の増加については株式分割、及び取引拡大に向け、同社の共栄会等に加入しており、同会における持株会での株式取得によるものであります。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":"holding restated onto a share base the issuer has not filed yet","pct_basis_period_end":"2026-02-28","pct_share_classes":1,"pct_of_holder_equity":0.09089777583326104,"pct_of_holder_assets":0.03761702641308386,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":["share split"],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"second_largest","held_name_raw":"㈱ジョイフル本田","held_name_en":"JOYFUL HONDA CO.,LTD.","held_sec_code":"3191","match_status":"matched","shares":296000,"book_value_yen":626000000,"prior_shares":296000,"prior_book_value_yen":592000000,"purpose_ja":"同社とは当社グループ会社が取り扱う商品の販売取引があり、中長期視点で取引深耕・拡大を目的に株式を保有しております。また、同社とは相応の取引金額を有しております。定量的な保有効果については、（注）に記載しております。","reciprocal":"無","pct_outstanding":0.48850114513910337,"pct_unavailable":null,"pct_basis_period_end":"2026-06-20","pct_share_classes":1,"pct_of_holder_equity":0.07870263854996046,"pct_of_holder_assets":0.03257020544203388,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"科研製薬㈱","held_name_en":"KAKEN PHARMACEUTICAL CO., LTD.","held_sec_code":"4521","match_status":"matched","shares":129565,"book_value_yen":536000000,"prior_shares":129565,"prior_book_value_yen":580000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.340351208087206,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.06738756272009394,"pct_of_holder_assets":0.02788758804621431,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"令和アカウンティング・ホールディングス㈱","held_name_en":"Reiwa Accounting Holdings Co., Ltd.","held_sec_code":"296A","match_status":"matched","shares":625000,"book_value_yen":495000000,"prior_shares":625000,"prior_book_value_yen":375000000,"purpose_ja":"・事業の円滑な取引関係維持のため保有しております。 ・定量的な保有効果については、（注）１に記載しております。","reciprocal":"無","pct_outstanding":1.6709889581049648,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.06223291706426586,"pct_of_holder_assets":0.02575439567700762,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"神栄㈱","held_name_en":"SHINYEI KAISHA","held_sec_code":"3004","match_status":"matched","shares":208500,"book_value_yen":481000000,"prior_shares":208500,"prior_book_value_yen":336000000,"purpose_ja":"・当社グループ事業の円滑な取引関係維持と資本業務提携による関係強化のため、保有しております。なお、当社は、同社が有する厳格な品質管理を必要とする医薬品・医療機器等の流通に対応するための製品及びその技術開発力を活用し、当社グループの医薬品・医療用機器等の流通機能を向上させること及び同社の食品関連事業等との協業を含めて包括的な資本業務提携をしております。 ・定量的な保有効果については、（注）１に記載しております。","reciprocal":"無","pct_outstanding":5.322271857051691,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.06047279415739774,"pct_of_holder_assets":0.025025988526546798,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"Ｈｅａｒｔｓｅｅｄ㈱","held_name_en":"Heartseed Inc.","held_sec_code":"219A","match_status":"matched","shares":250000,"book_value_yen":432000000,"prior_shares":416000,"prior_book_value_yen":911000000,"purpose_ja":"・当社グループ事業の円滑な取引関係維持と資本業務提携による関係強化のため保有しております。なお、当社は、iPS細胞由来の心筋球を用いた治療方法を開発する同社と、治験段階から当社グループの再生医療等製品の流通に関する経験とノウハウを活用し、患者様の治療に貢献することを目的として資本業務提携をしております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"無","pct_outstanding":1.0936994164019913,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":0.05431236398335929,"pct_of_holder_assets":0.022476563499933922,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"キッセイ薬品工業㈱","held_name_en":"KISSEI PHARMACEUTICAL CO., LTD.","held_sec_code":"4547","match_status":"matched","shares":88784,"book_value_yen":412000000,"prior_shares":88089,"prior_book_value_yen":338000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。・事業関係のより一層の強化のため、取引先持株会による取得により、保有株式数が695株増加しております。","reciprocal":"有","pct_outstanding":0.21418464234066875,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0517979026878334,"pct_of_holder_assets":0.021435981856418464,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"杏林製薬㈱","held_name_en":"KYORIN Pharmaceutical Co., Ltd.","held_sec_code":"4569","match_status":"matched","shares":200000,"book_value_yen":329000000,"prior_shares":200000,"prior_book_value_yen":300000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.344201252682597,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.04136288831140095,"pct_of_holder_assets":0.017117568035829308,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"サワイグループホールディングス㈱","held_name_en":"SAWAI GROUP HOLDINGS Co., Ltd.","held_sec_code":"4887","match_status":"matched","shares":146400,"book_value_yen":323000000,"prior_shares":146400,"prior_book_value_yen":290000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.12676901111087954,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.040608549922743174,"pct_of_holder_assets":0.01680539354277467,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"アリアケジャパン㈱","held_name_en":"ARIAKE JAPAN Co.,Ltd.","held_sec_code":"2815","match_status":"matched","shares":50000,"book_value_yen":280000000,"prior_shares":50000,"prior_book_value_yen":309000000,"purpose_ja":"・当社グループの食品加工原材料等卸売事業における主要取引先である同社との良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"無","pct_outstanding":0.15698792665511507,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.03520245813736251,"pct_of_holder_assets":0.014568143009216432,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"持田製薬㈱","held_name_en":"Mochida Pharmaceutical Co.,Ltd.","held_sec_code":"4534","match_status":"matched","shares":74882,"book_value_yen":259000000,"prior_shares":74882,"prior_book_value_yen":238000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.21123450974197241,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.03256227377706032,"pct_of_holder_assets":0.0134755322835252,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"ゼリア新薬工業㈱","held_name_en":"ZERIA PHARMACEUTICAL CO., LTD.","held_sec_code":"4559","match_status":"matched","shares":102300,"book_value_yen":224000000,"prior_shares":102300,"prior_book_value_yen":230000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.23208072507190985,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.028161966509890005,"pct_of_holder_assets":0.011654514407373145,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱ＰＲＩＳＭ　ＢｉｏＬａｂ","held_name_en":"PRISM BioLab Co.,LTD","held_sec_code":"206A","match_status":"matched","shares":922400,"book_value_yen":165000000,"prior_shares":922400,"prior_book_value_yen":258000000,"purpose_ja":"・事業の円滑な取引関係維持のため保有しております。 ・定量的な保有効果については、（注）１に記載しております。","reciprocal":"無","pct_outstanding":2.5058408041293125,"pct_unavailable":null,"pct_basis_period_end":"2025-09-30","pct_share_classes":1,"pct_of_holder_equity":0.02074430568808862,"pct_of_holder_assets":0.00858479855900254,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"Ｃｈｏｒｄｉａ　Ｔｈｅｒａｐｅｕｔｉｃｓ(株)","held_name_en":"Ｃｈｏｒｄｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ．","held_sec_code":"190A","match_status":"matched","shares":1307100,"book_value_yen":160000000,"prior_shares":1307100,"prior_book_value_yen":350000000,"purpose_ja":"・当社グループ事業の円滑な取引関係維持と業務提携による関係強化のため、保有しております。なお、当社は、がん領域に特化した研究開発を行う同社製品の市場への浸透を支援し、新たな治療法の提供と事業を拡大することを目的として、業務提携に関する基本合意書を締結しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"無","pct_outstanding":1.8946553643489958,"pct_unavailable":null,"pct_basis_period_end":"2025-08-31","pct_share_classes":1,"pct_of_holder_equity":0.020115690364207146,"pct_of_holder_assets":0.008324653148123674,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"ニプロ㈱","held_name_en":"NIPRO CORPORATION","held_sec_code":"8086","match_status":"matched","shares":79784,"book_value_yen":123000000,"prior_shares":79784,"prior_book_value_yen":108000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.048739400406777045,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.015463936967484243,"pct_of_holder_assets":0.006399577107620075,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"ロート製薬㈱","held_name_en":"ROHTO PHARMACEUTICAL CO.,LTD.","held_sec_code":"4527","match_status":"matched","shares":49508,"book_value_yen":119000000,"prior_shares":49508,"prior_book_value_yen":110000000,"purpose_ja":"・当社グループの化粧品・日用品、一般用医薬品卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.02190965467068671,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.014961044708379065,"pct_of_holder_assets":0.006191460778916983,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱大本組","held_name_en":"OHMOTO GUMI CO., LTD.","held_sec_code":"1793","match_status":"matched","shares":60000,"book_value_yen":102000000,"prior_shares":60000,"prior_book_value_yen":74000000,"purpose_ja":"・当社グループの事業所の建設・修繕等の取引があります。同社との良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.23211657823025036,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.012823752607182055,"pct_of_holder_assets":0.005306966381928843,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"日本化薬㈱","held_name_en":"NIPPON KAYAKU CO.,LTD.","held_sec_code":"4272","match_status":"matched","shares":38551,"book_value_yen":67000000,"prior_shares":38551,"prior_book_value_yen":54000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.0259646579994329,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.008423445340011743,"pct_of_holder_assets":0.003485948505776789,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱ファンペップ","held_name_en":"FunPep Company Limited","held_sec_code":"4881","match_status":"matched","shares":595200,"book_value_yen":48000000,"prior_shares":595200,"prior_book_value_yen":68000000,"purpose_ja":"・当社グループ事業の円滑な取引関係維持・強化のため、保有しております。なお、当社は、機能性ペプチドの研究開発を行う同社と、本成分を使用した医薬品の研究開発の促進および販売・流通にかかる優先交渉権の取得を目的として、提携契約を締結しております。  ・定量的な保有効果については、（注）１に記載しております。","reciprocal":"無","pct_outstanding":1.4673181506663577,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":0.006034707109262144,"pct_of_holder_assets":0.0024973959444371027,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"扶桑薬品工業㈱","held_name_en":"Fuso Pharmaceutical Industries, Ltd.","held_sec_code":"4538","match_status":"matched","shares":14301,"book_value_yen":33000000,"prior_shares":14301,"prior_book_value_yen":34000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.16751650947181052,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.004148861137617724,"pct_of_holder_assets":0.001716959711800508,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"フマキラー㈱","held_name_en":"FUMAKILLA LIMITED","held_sec_code":"4998","match_status":"matched","shares":20786,"book_value_yen":22000000,"prior_shares":20786,"prior_book_value_yen":22000000,"purpose_ja":"・当社グループの化粧品・日用品、一般用医薬品卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.12613476382348657,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0027659074250784826,"pct_of_holder_assets":0.0011446398078670053,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"小林製薬㈱","held_name_en":"KOBAYASHI PHARMACEUTICAL CO.,LTD.","held_sec_code":"4967","match_status":"matched","shares":3000,"book_value_yen":17000000,"prior_shares":3000,"prior_book_value_yen":17000000,"purpose_ja":"・当社グループの化粧品・日用品、一般用医薬品卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.004035577652585191,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":0.0021372921011970094,"pct_of_holder_assets":0.0008844943969881405,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱バイタルケーエスケー・ホールディングス","held_name_en":"VITAL KSK HOLDINGS,INC.","held_sec_code":"3151","match_status":"matched","shares":11361,"book_value_yen":16000000,"prior_shares":11361,"prior_book_value_yen":14000000,"purpose_ja":"・事業の円滑な取引関係維持のため保有しております。 ・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.023435819437624496,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0020115690364207145,"pct_of_holder_assets":0.0008324653148123675,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱メディカル一光グループ","held_name_en":"Medical Ikkou Group Co.,Ltd.","held_sec_code":"3353","match_status":"matched","shares":3200,"book_value_yen":9000000,"prior_shares":3200,"prior_book_value_yen":7000000,"purpose_ja":"・当社グループ事業の円滑な取引関係維持と業務提携による関係強化のため、保有しております。なお、当社は、調剤薬局事業等を行う同社と医薬品流通の改善、相互のノウハウ・情報交換を目的として、業務提携契約を締結しております。  ・定量的な保有効果については、（注）１に記載しております。","reciprocal":"無","pct_outstanding":0.08497304761146074,"pct_unavailable":null,"pct_basis_period_end":"2026-02-28","pct_share_classes":1,"pct_of_holder_equity":0.001131507582986652,"pct_of_holder_assets":0.00046826173958195675,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱スズケン","held_name_en":"SUZUKEN CO.,LTD.","held_sec_code":"9987","match_status":"matched","shares":1000,"book_value_yen":5000000,"prior_shares":1000,"prior_book_value_yen":4000000,"purpose_ja":"・事業の円滑な取引関係維持のため保有しております。 ・定量的な保有効果については、（注）１に記載しております。","reciprocal":"無","pct_outstanding":0.0014784609529000189,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0006286153238814733,"pct_of_holder_assets":0.0002601454108788648,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"東邦ホールディングス㈱","held_name_en":"TOHO HOLDINGS CO.,LTD.","held_sec_code":"8129","match_status":"matched","shares":1000,"book_value_yen":4000000,"prior_shares":1000,"prior_book_value_yen":4000000,"purpose_ja":"・事業の円滑な取引関係維持のため保有しております。 ・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.0015460910936463974,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0005028922591051786,"pct_of_holder_assets":0.00020811632870309187,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"アルフレッサ　ホールディングス㈱","held_name_en":"Alfresa Holdings Corporation","held_sec_code":"2784","match_status":"matched","shares":1000,"book_value_yen":2000000,"prior_shares":1000,"prior_book_value_yen":2000000,"purpose_ja":"・事業の円滑な取引関係維持のため保有しております。 ・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.0005488404921342925,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0002514461295525893,"pct_of_holder_assets":0.00010405816435154593,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱ほくやく・竹山ホールディングス","held_name_en":"HOKUYAKU TAKEYAMA Holdings,Inc.","held_sec_code":"3055","match_status":"matched","shares":1886,"book_value_yen":1000000,"prior_shares":1886,"prior_book_value_yen":1000000,"purpose_ja":"・事業の円滑な取引関係維持のため保有しております。 ・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.00917484749126784,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.00012572306477629465,"pct_of_holder_assets":5.202908217577297e-05,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"カンダホールディングス㈱","held_name_en":"Kanda Holdings Co.,Ltd.","held_sec_code":"9059","match_status":"matched","shares":2200,"book_value_yen":1000000,"prior_shares":2200,"prior_book_value_yen":1000000,"purpose_ja":"・当社グループの医薬品の運送等の取引があります。同社との良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.010268032999591146,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.00012572306477629465,"pct_of_holder_assets":5.202908217577297e-05,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱アインホールディングス","held_name_en":"AIN HOLDINGS INC.","held_sec_code":"9627","match_status":"matched","shares":100,"book_value_yen":0,"prior_shares":100,"prior_book_value_yen":0,"purpose_ja":"・事業の円滑な取引関係維持のため保有しております。 ・定量的な保有効果については、（注）１に記載しております。","reciprocal":"無","pct_outstanding":0.0002830062234200555,"pct_unavailable":null,"pct_basis_period_end":"2026-04-30","pct_share_classes":1,"pct_of_holder_equity":0.0,"pct_of_holder_assets":0.0,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"住友ファーマ㈱","held_name_en":"Sumitomo Pharma Co., Ltd.","held_sec_code":"4506","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":921788,"prior_book_value_yen":671000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しておりました。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱ホギメディカル","held_name_en":"ＨＯＧＹ ＭＥＤＩＣＡＬ ＣＯ.,ＬＴＤ.","held_sec_code":null,"match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":584000,"prior_book_value_yen":2803000000,"purpose_ja":"・当社グループの医療機器等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しておりました。","reciprocal":"有","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"鳥居薬品㈱","held_name_en":"TORII PHARMACEUTICAL CO., LTD.","held_sec_code":null,"match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":168988,"prior_book_value_yen":775000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しておりました。","reciprocal":"有","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2024-12-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"久光製薬㈱","held_name_en":"HISAMITSU PHARMACEUTICAL CO.,INC.","held_sec_code":null,"match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":187123,"prior_book_value_yen":757000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しておりました。","reciprocal":"有","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2025-02-28","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"メディカル・データ・ビジョン㈱","held_name_en":"Medical Data Vision Co.,Ltd.","held_sec_code":null,"match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":3212600,"prior_book_value_yen":1294000000,"purpose_ja":"・当社グループ事業の円滑な取引関係維持と資本業務提携による関係強化のため、保有しておりました。なお、当社は、医療機関向けシステムの開発・販売、医療データの分析等を行う同社と、医療・健康情報を利活用した医療サービス提供の実現を目的として、資本業務提携契約を締結しております。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false}],"holders":[{"holder_name":"田辺三菱製薬株式会社","holder_name_en":"Mitsubishi Tanabe Pharma Corporation","holder_sec_code":"4508","doc_id":"S100G3TB","period_end":"2019-03-31","holder_table":"reporting","shares":2125732,"book_value_yen":5590000000,"prior_shares":2125732,"prior_book_value_yen":4634000000,"purpose_ja":null,"reciprocal":"有","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":0.6227690607439361,"pct_of_holder_assets":0.5292127321577679,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":897604000000,"holder_total_assets_yen":1056286000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"塩野義製薬株式会社","holder_name_en":"Shionogi & Co., Ltd.","holder_sec_code":"4507","doc_id":"S100Z43Z","period_end":"2026-03-31","holder_table":"reporting","shares":1271605,"book_value_yen":3735000000,"prior_shares":1271605,"prior_book_value_yen":2969000000,"purpose_ja":"同社グループは当社の取引先の一つであるため、医薬品販売等における取引関係維持・強化のために株式を保有しております。2026年５月の取締役会において、個別の政策保有株式について、保有目的、保有に伴う便益・リスク、資本コスト等を総合的に検証し、経済合理性・戦略妥当性を確認しております。","reciprocal":"有","pct_outstanding":0.6212083224274639,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.22163344143032196,"pct_of_holder_assets":0.14494328390644465,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1685215000000,"holder_total_assets_yen":2576870000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"大塚ホールディングス株式会社","holder_name_en":"Otsuka Holdings Co., Ltd.","holder_sec_code":"4578","doc_id":"S100XUA7","period_end":"2025-12-31","holder_table":"largest","shares":1160494,"book_value_yen":3214000000,"prior_shares":1160494,"prior_book_value_yen":2762000000,"purpose_ja":"医薬品販売等に係る事業上の関係の維持・強化を目的として保有しています。これにより、大塚製薬㈱の事業基盤の安定化に資する協力関係の構築を図っています。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"有","pct_outstanding":0.5669280404898827,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.10595217844799508,"pct_of_holder_assets":0.07656825557311601,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"日本新薬株式会社","holder_name_en":"Nippon Shinyaku Co., Ltd.","holder_sec_code":"4516","doc_id":"S100YGRG","period_end":"2026-03-31","holder_table":"reporting","shares":791710,"book_value_yen":2326000000,"prior_shares":791710,"prior_book_value_yen":1848000000,"purpose_ja":"医薬品事業の販売取引関係の維持・強化を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証し、2026年4月の取締役会において検証結果を確認、保有の可否を判断しています。","reciprocal":"有","pct_outstanding":0.3867685648837866,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.797802099804151,"pct_of_holder_assets":0.6715575457834212,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"小野薬品工業株式会社","holder_name_en":"ONO　PHARMACEUTICAL　CO.,　LTD.","holder_sec_code":"4528","doc_id":"S100YOIE","period_end":"2026-03-31","holder_table":"reporting","shares":591038,"book_value_yen":1736000000,"prior_shares":591038,"prior_book_value_yen":1380000000,"purpose_ja":"取引先(特約店)として、事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":0.28873567221808927,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.20406076214813917,"pct_of_holder_assets":0.15688897122949078,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社ホギメディカル","holder_name_en":"ＨＯＧＹ ＭＥＤＩＣＡＬ ＣＯ.,ＬＴＤ.","holder_sec_code":"3593","doc_id":"S100VZOE","period_end":"2025-03-31","holder_table":"reporting","shares":700000,"book_value_yen":1634000000,"prior_shares":700000,"prior_book_value_yen":1624000000,"purpose_ja":"当社製品の販売を中心とした取引先であり、営業上の取引関係の維持強化等を目的に保有しております。","reciprocal":"有","pct_outstanding":0.3366189879211586,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":2.198245708443201,"pct_of_holder_assets":1.6691352980233924,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":74332000000,"holder_total_assets_yen":97895000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"杏林製薬株式会社","holder_name_en":"KYORIN Pharmaceutical Co., Ltd.","holder_sec_code":"4569","doc_id":"S100YDHG","period_end":"2026-03-31","holder_table":"reporting","shares":431280,"book_value_yen":1267000000,"prior_shares":431280,"prior_book_value_yen":1007000000,"purpose_ja":"医薬品の安定供給を図るため、同社の充実した販売網を経常的に活用するために保有するものであり、当社の持続成長や企業価値向上の観点から総合的に保有の適否を検証しております","reciprocal":"有","pct_outstanding":0.2106902106365708,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.8895910128137616,"pct_of_holder_assets":0.6482310506254637,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":142425000000,"holder_total_assets_yen":195455000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"科研製薬株式会社","holder_name_en":"KAKEN PHARMACEUTICAL CO., LTD.","holder_sec_code":"4521","doc_id":"S100YK2Q","period_end":"2026-03-31","holder_table":"reporting","shares":380838,"book_value_yen":1118000000,"prior_shares":380838,"prior_book_value_yen":889000000,"purpose_ja":"医薬品販売に係る取引円滑化のため、当社の持続成長や企業価値向上から総合的に判断し保有しております。","reciprocal":"有","pct_outstanding":0.1860481321610331,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.7573550830177687,"pct_of_holder_assets":0.6273251148880298,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":147619000000,"holder_total_assets_yen":178217000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"参天製薬株式会社","holder_name_en":"SANTEN PHARMACEUTICAL CO., LTD.","holder_sec_code":"4536","doc_id":"S100YDH1","period_end":"2026-03-31","holder_table":"reporting","shares":373800,"book_value_yen":1098000000,"prior_shares":373800,"prior_book_value_yen":873000000,"purpose_ja":"当社医薬品等の販売契約があり、眼科領域における事業関係の強化を図ることを目的に保有しています。（注）","reciprocal":"有","pct_outstanding":0.18260990710431776,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.36971066268447655,"pct_of_holder_assets":0.25955421917439064,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":296989000000,"holder_total_assets_yen":423033000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"キッセイ薬品工業株式会社","holder_name_en":"KISSEI PHARMACEUTICAL CO., LTD.","holder_sec_code":"4547","doc_id":"S100YFN3","period_end":"2026-03-31","holder_table":"reporting","shares":373325,"book_value_yen":1096000000,"prior_shares":373325,"prior_book_value_yen":871000000,"purpose_ja":"同社は医薬品事業における取引先の一つであるため、取引関係維持・強化のために株式を保有しています。具体的には、医療用医薬品の販売先です。2026年４月の取締役会において、個別の政策保有株式について、保有目的、保有に伴う便益・リスク、資本コスト等を総合的に検証し、経済合理性・戦略妥当性を確認しています。","reciprocal":"有","pct_outstanding":0.18237785866698616,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.4733605141317117,"pct_of_holder_assets":0.398420857477298,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":231536000000,"holder_total_assets_yen":275086000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社ツムラ","holder_name_en":"TSUMURA & CO.","holder_sec_code":"4540","doc_id":"S100YFC1","period_end":"2026-03-31","holder_table":"reporting","shares":347319,"book_value_yen":1020000000,"prior_shares":1157919,"prior_book_value_yen":2703000000,"purpose_ja":"医薬品販売等の取引関係を維持・強化し、中長期的な企業価値の向上のため保有しており、当社の資本コストと配当金・取引額の比較等により、当社に便益があることを確認しています。","reciprocal":"有","pct_outstanding":0.16967332885383773,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.27448648154078414,"pct_of_holder_assets":0.17207464665652214,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":371603000000,"holder_total_assets_yen":592766000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"日医工株式会社","holder_name_en":"Nichi-Iko Pharmaceutical Co., Ltd.","holder_sec_code":"4541","doc_id":"S100OLZH","period_end":"2022-03-31","holder_table":"reporting","shares":468050,"book_value_yen":943000000,"prior_shares":466684,"prior_book_value_yen":991000000,"purpose_ja":"(保有目的)当社の販売先である医薬品卸であり、販売協力関係構築を目的として保有しております。(株式が増加した理由)販売協力関係の強化を目的とした株式取得（取引先持株会を通じた株式取得）。","reciprocal":"有","pct_outstanding":0.2229208700780877,"pct_unavailable":null,"pct_basis_period_end":"2022-03-31","pct_share_classes":1,"pct_of_holder_equity":7.040465880244886,"pct_of_holder_assets":0.3619141921791226,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":13394000000,"holder_total_assets_yen":260559000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"持田製薬株式会社","holder_name_en":"Mochida Pharmaceutical Co.,Ltd.","holder_sec_code":"4534","doc_id":"S100YI28","period_end":"2026-03-31","holder_table":"reporting","shares":319100,"book_value_yen":937000000,"prior_shares":319100,"prior_book_value_yen":745000000,"purpose_ja":"取引関係の維持・強化のため、保有しております。保有効果を定量的に量りかねるため、取引関係への影響を含む現在及び将来の意義を総合的に判断のうえ、保有の適否を取締役会において、検証しました。なお、同社子会社と医薬品販売等の重要な取引を行っております。","reciprocal":"有","pct_outstanding":0.15588769758423704,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.6677308552941009,"pct_of_holder_assets":0.5128064798598949,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":140326000000,"holder_total_assets_yen":182720000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"サワイグループホールディングス株式会社","holder_name_en":"SAWAI GROUP HOLDINGS Co., Ltd.","holder_sec_code":"4887","doc_id":"S100YITS","period_end":"2026-03-31","holder_table":"largest","shares":218100,"book_value_yen":641000000,"prior_shares":218100,"prior_book_value_yen":509000000,"purpose_ja":"有力医薬品卸として良好な関係を維持していくことの重要性を考慮して保有しております。なお、定期的に定量的な保有効果を検証しております。","reciprocal":"有","pct_outstanding":0.1065468719621501,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.3589910168238536,"pct_of_holder_assets":0.17809562707164667,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":178556000000,"holder_total_assets_yen":359919000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"大正製薬ホールディングス株式会社","holder_name_en":"TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.","holder_sec_code":"4581","doc_id":"S100R80T","period_end":"2023-03-31","holder_table":"reporting","shares":317308,"book_value_yen":572000000,"prior_shares":317308,"prior_book_value_yen":639000000,"purpose_ja":"当社医薬事業における販売取引関係の維持・強化のために保有しています。","reciprocal":"有","pct_outstanding":0.15112650802520583,"pct_unavailable":null,"pct_basis_period_end":"2023-03-31","pct_share_classes":1,"pct_of_holder_equity":0.07067460891117858,"pct_of_holder_assets":0.06075476107021848,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":809343000000,"holder_total_assets_yen":941490000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"鳥居薬品株式会社","holder_name_en":"TORII PHARMACEUTICAL CO., LTD.","holder_sec_code":"4551","doc_id":"S100VH2F","period_end":"2024-12-31","holder_table":"reporting","shares":221746,"book_value_yen":527000000,"prior_shares":221746,"prior_book_value_yen":506000000,"purpose_ja":"医薬品の販売等における円滑な取引関係を維持するために取得後、継続保有（注）２","reciprocal":"有","pct_outstanding":0.10663416299366461,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.4336270807105889,"pct_of_holder_assets":0.3746516521640221,"holder_equity_basis":"parent_only","holder_equity_yen":121533000000,"holder_total_assets_yen":140664000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社大本組","holder_name_en":"OHMOTO GUMI CO., LTD.","holder_sec_code":"1793","doc_id":"S100YI8J","period_end":"2026-03-31","holder_table":"reporting","shares":133280,"book_value_yen":391000000,"prior_shares":133280,"prior_book_value_yen":311000000,"purpose_ja":"主要発注者として同社より工事を受注しております。今後も継続して保有することにより、良好な関係の維持・強化を通じて、当社の中長期的な企業価値の向上を図ることを目的としております。","reciprocal":"有","pct_outstanding":0.0651103489001163,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.5691411935953421,"pct_of_holder_assets":0.3775078687701547,"holder_equity_basis":"parent_only","holder_equity_yen":68700000000,"holder_total_assets_yen":103574000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"久光製薬株式会社","holder_name_en":"HISAMITSU PHARMACEUTICAL CO.,INC.","holder_sec_code":"4530","doc_id":"S100VT69","period_end":"2025-02-28","holder_table":"reporting","shares":176458,"book_value_yen":387000000,"prior_shares":176458,"prior_book_value_yen":399000000,"purpose_ja":"医薬品事業の販売先であり、取引関係維持・強化を図るため。","reciprocal":"有","pct_outstanding":0.08485587624370257,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.13850762507739606,"pct_of_holder_assets":0.11280562454090734,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"ニチバン株式会社","holder_name_en":"NICHIBAN CO., LTD.","holder_sec_code":"4218","doc_id":"S100YGTG","period_end":"2026-03-31","holder_table":"reporting","shares":85404,"book_value_yen":250000000,"prior_shares":85404,"prior_book_value_yen":199000000,"purpose_ja":"メディカル事業における販売先であり、中長期的な提携関係を維持するため保有しております。","reciprocal":"無","pct_outstanding":0.04172182050919517,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.5640157924421884,"pct_of_holder_assets":0.3714323918760307,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":44325000000,"holder_total_assets_yen":67307000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"カンダホールディングス株式会社","holder_name_en":"Kanda Holdings Co.,Ltd.","holder_sec_code":"9059","doc_id":"S100YHF0","period_end":"2026-03-31","holder_table":"reporting","shares":60180,"book_value_yen":176000000,"prior_shares":60180,"prior_book_value_yen":140000000,"purpose_ja":"（保有目的）継続的取引関係の維持（定量的な保有効果）（注）１（営業上の取引）販売先","reciprocal":"有","pct_outstanding":0.02939931570234843,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.6265351892065074,"pct_of_holder_assets":0.366155574510579,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":28091000000,"holder_total_assets_yen":48067000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社　マルタイ","holder_name_en":"MARUTAI CO.,LTD.","holder_sec_code":"2919","doc_id":"S100YG8L","period_end":"2026-03-31","holder_table":"reporting","shares":59386,"book_value_yen":174476000,"prior_shares":59386,"prior_book_value_yen":138666000,"purpose_ja":"（保有目的）原材料の主要仕入業者であるＭＰ五協フード＆ケミカル㈱の親会社であり、同社グループとの安定的な取引関係の維持・強化を目的に保有しております。（定量的な保有効果）（注）２","reciprocal":"無（注）３","pct_outstanding":0.029011428419735193,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.6809898027441188,"pct_of_holder_assets":1.2679705958958902,"holder_equity_basis":"parent_only","holder_equity_yen":10379361000,"holder_total_assets_yen":13760256000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"ニプロ株式会社","holder_name_en":"NIPRO CORPORATION","holder_sec_code":"8086","doc_id":"S100YJLK","period_end":"2026-03-31","holder_table":"reporting","shares":44500,"book_value_yen":130000000,"prior_shares":44500,"prior_book_value_yen":103000000,"purpose_ja":"(保有目的)医療用医薬品の取引先であり、取引関係を維持・強化させるため保有しています。","reciprocal":"有","pct_outstanding":0.021739274655275927,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.038832399364343496,"pct_of_holder_assets":0.010714668381013608,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":334772000000,"holder_total_assets_yen":1213290000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"テルモ株式会社","holder_name_en":"TERUMO CORPORATION","holder_sec_code":"4543","doc_id":"S100YGMG","period_end":"2026-03-31","holder_table":"reporting","shares":43303,"book_value_yen":127000000,"prior_shares":43303,"prior_book_value_yen":101000000,"purpose_ja":"主にメディカルケアソリューションズカンパニーにおける代理店取引関係維持・強化のため保有しております。 ","reciprocal":"有","pct_outstanding":0.0211545125932003,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.008015101208008284,"pct_of_holder_assets":0.005492523680561742,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1584509000000,"holder_total_assets_yen":2312234000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"ゼリア新薬工業株式会社","holder_name_en":"ZERIA PHARMACEUTICAL CO., LTD.","holder_sec_code":"4559","doc_id":"S100YKC2","period_end":"2026-03-31","holder_table":"reporting","shares":42736,"book_value_yen":125558000,"prior_shares":42736,"prior_book_value_yen":99788000,"purpose_ja":"（保有目的）医療用医薬品事業活動の円滑な推進（定量的な保有効果）（注）１","reciprocal":"有","pct_outstanding":0.02087752003748027,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.1156100021002757,"pct_of_holder_assets":0.0698716934159332,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":108604790000,"holder_total_assets_yen":179697949000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"日本化薬株式会社","holder_name_en":"NIPPON KAYAKU CO.,LTD.","holder_sec_code":"4272","doc_id":"S100YD4R","period_end":"2026-03-31","holder_table":"reporting","shares":34038,"book_value_yen":100000000,"prior_shares":34038,"prior_book_value_yen":79000000,"purpose_ja":"（保有目的）ライフサイエンス事業領域における販売先として関係の維持、強化を図るため（定量的な保有効果）　（注）1","reciprocal":"有","pct_outstanding":0.016628346757669256,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.03570102533344758,"pct_of_holder_assets":0.025079250431363106,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":280104000000,"holder_total_assets_yen":398736000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"ロート製薬株式会社","holder_name_en":"ROHTO PHARMACEUTICAL CO.,LTD.","holder_sec_code":"4527","doc_id":"S100YE5N","period_end":"2026-03-31","holder_table":"reporting","shares":33000,"book_value_yen":96000000,"prior_shares":33000,"prior_book_value_yen":77000000,"purpose_ja":"同社は、医薬品等の卸売事業を営んでおり、当社製品の流通・販売において重要な取引関係を有しております。特に再生医療関連製品の流通及び医療機関向け情報提供において連携しており、当該関係の維持・強化を通じて安定供給及び販売機会の拡大を図ることを目的として、同社株式を保有しております。","reciprocal":"有","pct_outstanding":0.016121259856721474,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.029983696365101477,"pct_of_holder_assets":0.019762398331724208,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":320174000000,"holder_total_assets_yen":485771000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"セコム株式会社","holder_name_en":"SECOM CO., LTD.","holder_sec_code":"9735","doc_id":"S100YICV","period_end":"2026-03-31","holder_table":"reporting","shares":30690,"book_value_yen":90000000,"prior_shares":30690,"prior_book_value_yen":71000000,"purpose_ja":"主にセキュリティサービス事業におけるサービスおよび商品の取引等、取引関係の維持拡大を目的に保有しております。定量的な保有効果は個別の取引条件等に関わるため記載しておりませんが、(1)に記載の方法で2025年10月に保有の妥当性の検証を行いました。","reciprocal":"無","pct_outstanding":0.014992771666750969,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0060012722697211805,"pct_of_holder_assets":0.004035644606786968,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":1499682000000,"holder_total_assets_yen":2230127000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"フマキラー株式会社","holder_name_en":"FUMAKILLA LIMITED","holder_sec_code":"4998","doc_id":"S100YGPK","period_end":"2026-03-31","holder_table":"reporting","shares":19965,"book_value_yen":58000000,"prior_shares":19965,"prior_book_value_yen":46000000,"purpose_ja":"販売取引関係の維持・発展のため（定量的な保有効果）（注）","reciprocal":"有","pct_outstanding":0.009753362213316491,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.19776997306236574,"pct_of_holder_assets":0.08460236886632826,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":29327000000,"holder_total_assets_yen":68556000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"川本産業株式会社","holder_name_en":"KAWAMOTO CORPORATION","holder_sec_code":"3604","doc_id":"S100TT3D","period_end":"2024-03-31","holder_table":"reporting","shares":24664,"book_value_yen":57220000,"prior_shares":24406,"prior_book_value_yen":44028000,"purpose_ja":"同社傘下の企業数社は当社の販売先であり、良好な取引関係の維持、強化を目的として保有しております。株式数の増加は、取引先持株会を通じた株式の取得による増加であります。","reciprocal":"無","pct_outstanding":0.011743803274877439,"pct_unavailable":null,"pct_basis_period_end":"2024-03-31","pct_share_classes":1,"pct_of_holder_equity":0.7382504702443903,"pct_of_holder_assets":0.2926946145520887,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":7750757000,"holder_total_assets_yen":19549386000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"大木ヘルスケアホールディングス株式会社","holder_name_en":"OHKI HEALTHCARE HOLDINGS CO.,LTD.","holder_sec_code":"3417","doc_id":"S100YF0K","period_end":"2026-03-31","holder_table":"largest","shares":10000,"book_value_yen":29000000,"prior_shares":10000,"prior_book_value_yen":23000000,"purpose_ja":"・同社株式は、当社グループの事業活動の円滑化のため保有しております。・同社グループは、当社グループにおける販売先であり、当社の事業継続に不可欠な取引先であります。・当社グループは保有株式について、配当・取引額に加え、経営戦略上の重要性や事業上の関係等を総合的に判断し、保有の便益とリスクの見合いを勘案し保有しております。定量的な保有効果については、取引先との関係性を考慮し記載しませんが、上記方針に基づいて総合的に保有効果を判断しております。 ","reciprocal":"無","pct_outstanding":0.0048852302596125675,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.08487970496985307,"pct_of_holder_assets":0.019542700801250732,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":34166000000,"holder_total_assets_yen":148393000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"扶桑薬品工業株式会社","holder_name_en":"Fuso Pharmaceutical Industries, Ltd.","holder_sec_code":"4538","doc_id":"S100YHSC","period_end":"2026-03-31","holder_table":"reporting","shares":5000,"book_value_yen":14000000,"prior_shares":5000,"prior_book_value_yen":11000000,"purpose_ja":"・製商品の販売を行う取引先企業との業務　のより円滑な推進・株価の評価益及び受取配当金の発生","reciprocal":"有","pct_outstanding":0.0024426151298062838,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.039934963060159166,"pct_of_holder_assets":0.015499928036048403,"holder_equity_basis":"parent_only","holder_equity_yen":35057000000,"holder_total_assets_yen":90323000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社構造計画研究所ホールディングス","holder_name_en":"KOZO KEIKAKU ENGINEERING HOLDINGS Inc.","holder_sec_code":"208A","doc_id":"S100Z0JO","period_end":"2026-06-30","holder_table":"reporting","shares":1700,"book_value_yen":4457000,"prior_shares":1700,"prior_book_value_yen":3972000,"purpose_ja":"当社のサービスに係る業務の円滑な推進のために保有しており、前述の検証方法に従い合理性について判断しております。定量的な保有効果については情報保護の観点から記載が困難であります。","reciprocal":"無","pct_outstanding":0.0008304891441341365,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.03855626385737383,"pct_of_holder_assets":0.019812715825021136,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":11559730000,"holder_total_assets_yen":22495654000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"ＣＢグループマネジメント株式会社","holder_name_en":"CB GROUP MANAGEMENT Co., Ltd.","holder_sec_code":"9852","doc_id":"S100TS8T","period_end":"2024-03-31","holder_table":"reporting","shares":null,"book_value_yen":4000000,"prior_shares":null,"prior_book_value_yen":3000000,"purpose_ja":"（保有目的）同社に日用雑貨品を販売しています。同社との取引関係の維持、強化のため同社株式を継続保有しています。（定量的な保有効果）（注）１","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2024-03-31","pct_share_classes":1,"pct_of_holder_equity":0.01620285980475554,"pct_of_holder_assets":0.007518655664367211,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":24687000000,"holder_total_assets_yen":53201000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社　構造計画研究所","holder_name_en":"KOZO KEIKAKU ENGINEERING Inc.","holder_sec_code":"4748","doc_id":"S100RTM1","period_end":"2023-06-30","holder_table":"reporting","shares":1700,"book_value_yen":3996000,"prior_shares":1700,"prior_book_value_yen":3253000,"purpose_ja":"当社のサービスに係る業務の円滑な推進のために保有しており、前述の検証方法に従い合理性について判断しております。定量的な保有効果については情報保護の観点から記載が困難であります。","reciprocal":"無","pct_outstanding":0.0008096709305874731,"pct_unavailable":null,"pct_basis_period_end":"2023-03-31","pct_share_classes":1,"pct_of_holder_equity":0.042959912145044535,"pct_of_holder_assets":0.021826678909124875,"holder_equity_basis":"parent_only","holder_equity_yen":9301695000,"holder_total_assets_yen":18307870000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"東邦ホールディングス株式会社","holder_name_en":"TOHO HOLDINGS CO.,LTD.","holder_sec_code":"8129","doc_id":"S100YHSN","period_end":"2026-03-31","holder_table":"reporting","shares":100,"book_value_yen":0,"prior_shares":100,"prior_book_value_yen":0,"purpose_ja":"同上","reciprocal":"有","pct_outstanding":4.885230259612567e-05,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0,"pct_of_holder_assets":0.0,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"アルフレッサホールディングス株式会社","holder_name_en":"Alfresa Holdings Corporation","holder_sec_code":"2784","doc_id":"S100YH29","period_end":"2026-03-31","holder_table":"largest","shares":100,"book_value_yen":0,"prior_shares":100,"prior_book_value_yen":0,"purpose_ja":"・同業界内における関係維持発展に伴う中　長期的な企業価値の向上・当社グループの取引先・検証実施(注)１","reciprocal":"有","pct_outstanding":4.885230259612567e-05,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0,"pct_of_holder_assets":0.0,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":507903000000,"holder_total_assets_yen":1507016000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"あすか製薬ホールディングス株式会社","holder_name_en":"ASKA Pharmaceutical Holdings Co., Ltd.","holder_sec_code":"4886","doc_id":"S100YEAY","period_end":"2026-03-31","holder_table":"largest","shares":null,"book_value_yen":null,"prior_shares":136911,"prior_book_value_yen":319000000,"purpose_ja":"医薬品事業等における特約店であり、中長期的な取引関係の維持と強化を図るため保有しておりましたが、当事業年度に売却しております。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":76819000000,"holder_total_assets_yen":112379000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"住友ファーマ株式会社","holder_name_en":"Sumitomo Pharma Co., Ltd.","holder_sec_code":"4506","doc_id":"S100YH3M","period_end":"2026-03-31","holder_table":"reporting","shares":null,"book_value_yen":null,"prior_shares":1084000,"prior_book_value_yen":2531000000,"purpose_ja":"重要な特約店として同社と良好な関係を維持・強化していくことの事業上の必要性等に加え、資本コストを勘案した配当・取引額等の定量的な評価の実施を通じて、総合的に判断し保有していました。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":292467000000,"holder_total_assets_yen":804571000000,"implausible":false,"reciprocal_held_both_ways":false}],"reclassified":[],"reclassified_note":"As filed, from the annual report's 保有目的を変更した投資株式 table. direction=to_pure means the filer moved the holding from a policy shareholding to 純投資目的 (pure investment); the shares are not necessarily sold, and the position leaves the named policy table in the year of the change. direction=to_policy is the reverse. fy_of_change_ja is the fiscal year the filer states the change took effect, verbatim — some filers list more than one. A filing repeats these rows for several years after the change, so this is a standing disclosure, not a one-year event.","implausible_note":"A row is flagged implausible when its two filed numbers are mutually impossible — book value ÷ shares of ¥1,000,000 or more, which no listed Japanese share reaches. It is a filer tagging error (a value entered at the wrong scale, or a share count in thousands), not an extraction error: the values match the filing's XBRL exactly. Flagged rows are still returned, exactly as filed, but are excluded from the yen aggregates here and counted in excluded_positions / excluded_yen so the exclusion is visible.","notes":[{"holder_table":"reporting","note_no":"1","text_ja":"（注）１．当社は、特定投資株式における定量的な保有効果の記載が困難であるため、保有の合理性を検証した方法について記載いたします。　当該合理性は、主たる事業の社会的意義や取引関係強化による収益への貢献度に加え、取引先の成長性や資本コストを意識した現時点あるいは将来の採算性・収益性等を踏まえ、当社グループの企業価値の維持・向上に資するものであるかを検証しております。"},{"holder_table":"reporting","note_no":"2","text_ja":"２．当社の株式の保有の有無には、投資先の子会社が保有する場合も含めております。"},{"holder_table":"second_largest","note_no":"1","text_ja":"（注）各銘柄の定量的な保有効果の記載は実務上困難なため記載を省略しております。なお、保有の合理性は、取引先から得られる又は得られる見込みがある利益等と資本コストの比較を行い保有の合理性を検証しております。"}],"notes_note":"The filing's own numbered footnotes to the named policy table, verbatim. The XBRL numbers them (注)1, (注)2 … and gives no link back to a row, so a note is tied to a position only where it names that issuer.","flows":[{"holder_table":"reporting","share_class":"listed","issues_increased":2,"acquisition_cost_yen":7000000,"issues_decreased":9,"sale_proceeds_yen":22910000000,"entity_scope":"parent_only","share_scope":"listed"},{"holder_table":"reporting","share_class":"unlisted","issues_increased":null,"acquisition_cost_yen":null,"issues_decreased":null,"sale_proceeds_yen":null,"entity_scope":"parent_only","share_scope":"unlisted"},{"holder_table":"second_largest","share_class":"listed","issues_increased":14,"acquisition_cost_yen":91000000,"issues_decreased":5,"sale_proceeds_yen":2743000000,"entity_scope":"second_largest_holding_company","share_scope":"listed"},{"holder_table":"second_largest","share_class":"unlisted","issues_increased":1,"acquisition_cost_yen":299000000,"issues_decreased":1,"sale_proceeds_yen":0,"entity_scope":"second_largest_holding_company","share_scope":"unlisted"}],"flows_note":"The filer's own tally, as filed, of how many issues increased or decreased during the year and the yen involved — acquisition cost for increases, sale proceeds for decreases. Read against the reclassification table this separates what was actually sold from what merely changed category. Counts are as filed and are not corrected for filer tagging errors.","no_reduction_measure":"This product holds sale proceeds (売却価額), as filed, for one fiscal year. It does NOT hold a book-value-reduction measure. The two are different measures and must never be presented as equivalent.","scale":{"policy_total_yen":126082000000,"listed_yen":122646000000,"unlisted_yen":3436000000,"listed_issues":72,"unlisted_issues":30,"equity_yen":795399000000,"equity_basis":"jgaap_consolidated","total_assets_yen":1922002000000,"assets_basis":"jgaap_consolidated","pct_of_equity":15.851415453124783,"pct_of_assets":6.559930738885807,"equity_basis_label":"Consolidated net assets (Japanese GAAP)","assets_basis_label":"Consolidated net assets (Japanese GAAP)","equity_calc":"total policy shareholdings ÷ shareholders' equity × 100, both as filed in this annual securities report","assets_calc":"total policy shareholdings ÷ total assets × 100, both as filed in this annual securities report"},"scale_entities":[{"holder_table":"reporting","share_class":"listed","book_value_yen":93783000000,"issue_count":41,"holder_table_label":"The filer itself","entity_scope":"parent_only","share_scope":"listed"},{"holder_table":"reporting","share_class":"unlisted","book_value_yen":2947000000,"issue_count":21,"holder_table_label":"The filer itself","entity_scope":"parent_only","share_scope":"unlisted"},{"holder_table":"second_largest","share_class":"listed","book_value_yen":28863000000,"issue_count":31,"holder_table_label":"Second largest holder in the group","entity_scope":"second_largest_holding_company","share_scope":"listed"},{"holder_table":"second_largest","share_class":"unlisted","book_value_yen":489000000,"issue_count":9,"holder_table_label":"Second largest holder in the group","entity_scope":"second_largest_holding_company","share_scope":"unlisted"}],"scale_history":[{"year":"2022","period_end":"2022-03-31","policy_total_yen":105904000000,"equity_yen":649089000000,"equity_basis":"jgaap_consolidated","pct_of_equity":16.31579028453725,"pct_of_assets":6.195122008290269},{"year":"2023","period_end":"2023-03-31","policy_total_yen":96725000000,"equity_yen":688055000000,"equity_basis":"jgaap_consolidated","pct_of_equity":14.057742476982218,"pct_of_assets":5.676779521454383},{"year":"2024","period_end":"2024-03-31","policy_total_yen":100881000000,"equity_yen":736612000000,"equity_basis":"jgaap_consolidated","pct_of_equity":13.695269694221652,"pct_of_assets":5.607219501458207},{"year":"2025","period_end":"2025-03-31","policy_total_yen":95416000000,"equity_yen":757947000000,"equity_basis":"jgaap_consolidated","pct_of_equity":12.588743012374216,"pct_of_assets":5.2283198099271},{"year":"2026","period_end":"2026-03-31","policy_total_yen":126082000000,"equity_yen":795399000000,"equity_basis":"jgaap_consolidated","pct_of_equity":15.851415453124783,"pct_of_assets":6.559930738885807}],"scale_note":"The policy total is Official (as filed) — the filing's own total carrying amount for the whole policy bucket, listed and unlisted, summed across the entities the filing discloses. It is a floor: holdings at group companies the filing does not name are disclosed nowhere and are not included. The percentages are calculated, not filed, and carry their formula. equity_basis names which figure the denominator is, because filers report under Japanese, IFRS or US accounting standards and an adopter of the latter two stops tagging the Japanese consolidated figure — a parent-only denominator is a different measure and is labelled as one, never silently mixed with a group figure. Percentages are null where equity or total assets is missing or not positive; missing is never shown as zero.","scale_reference":"ISS's Japan proxy voting guidelines recommend a vote against the top executive at a company that allocates 20 percent or more of its net assets to cross-shareholdings, a policy effective from February 2022. ISS counts unilateral holdings, not only mutual ones.","ownership_calc":"shares held ÷ (issuer's issued shares − treasury shares) × 100, both as filed, the denominator taken from the issuer's own annual securities report nearest the holding's fiscal year end","ownership_note":"Derived, not filed. The denominator is the issuer's own reported issued shares less treasury shares, from its annual report nearest this holding's fiscal year end on either side — pct_basis_period_end gives that date, and it can fall after the holding's date where that report is the closer one. For a single-class listed stock this equals the stake's share of market capitalisation. It is null where the issuer files no annual report we hold; where the issuer's share count moves by half or more across the window, because a split or issue makes the share base indeterminate; and where the result would exceed 100%, which is a data fault rather than a stake. It is less exact where the issuer has more than one share class (pct_share_classes > 1), because treasury shares are reported across all classes.","holder_share_calc":"this position's book value ÷ the holder's shareholders' equity (or total assets) × 100, both as filed in the holder's own annual securities report","holder_share_note":"The mirror of pct_outstanding. That sizes a stake against the ISSUER — how much of the issuer this holder owns. pct_of_holder_equity and pct_of_holder_assets size the same position against the HOLDER: how much of its own capital is committed to this one name. Calculated, not filed. Null where the holder's filing gives no usable denominator, never zero. holder_equity_basis says which accounting figure the denominator is, and a parent_only basis is not comparable with a consolidated one. A position CAN legitimately exceed 100% of equity — a holder whose book equity is smaller than one long-held stake is a real and commercially interesting case, not an error — so no ceiling is imposed. Extreme values are worth checking against the filing: where the position's own two filed numbers are mutually impossible the row is marked `implausible`, but that test catches only scale errors visible per share, so it does not catch every bad figure. The book value and share count are returned alongside so the reader can check.","action_calc":"keyword match over the filing's own stated purpose and table footnotes: 株式分割、株式併合、株式交換、株式移転、会社分割、合併、持株会社、商号変更、公開買付、上場廃止","ratio_calc":"current shares ÷ prior shares where that ratio is an exact whole number (or its exact reciprocal) — the signature of a split or a consolidation rather than a trade","history":[{"year":"2022","period_end":"2022-03-31","named_holdings":66,"book_value_yen":101611000000},{"year":"2023","period_end":"2023-03-31","named_holdings":51,"book_value_yen":91773000000},{"year":"2024","period_end":"2024-03-31","named_holdings":44,"book_value_yen":96839000000},{"year":"2025","period_end":"2025-03-31","named_holdings":48,"book_value_yen":92225000000},{"year":"2026","period_end":"2026-03-31","named_holdings":56,"book_value_yen":119077000000}],"history_note":"One point per annual report filed. Each year's book value is as filed; book values are fair-valued at period end, so a change reflects both trading and market moves.","provenance":{"trust":"official","note":"Figures exactly as filed in each company's 有価証券報告書 (annual securities report), EDINET. Raw filings archived with SHA-256; doc_id links to the source filing."}}